LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday its joint venture specialist HIV company ViiV Healthcare Ltd's study of a combined maraviroc treatment showed inferior efficacy compared to an alternative combination.
ViiV Healthcare presented an analysis of the results of the study Tuesday at the 20th International AIDS Congress in Melbourne.
The Phase III study compared maraviroc, marketed as Celsentri, combined with darunavir/ritonavir, when compared to emtricitabine/tenofovir. The study did not meet its non-inferiority endpoint, it said.
Secondary endpoints included the safety and tolerability of maraviroc, as well as the utility of genotypic and phenotypic testing and tropism change. Glaxo said there were no new or unique safety findings.
ViiV decided to terminate the study in October 2013 following a preliminary review of the 48 week primary clinical efficacy data, although it said this decision was not based on any new or unique drug related safety events.
ViiV was created in a joint venture between Glaxo and US based Pfizer Inc in 2009, and also has Shionogi Ltd as a shareholder.
Shares in Glaxo were trading down 0.3% at 1,551.80 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.